PURPOSE: Lethal giant larvae functions as a cell polarity regulator and a tumor suppressor in Drosophila. Its evolutionary conservation implies a tumor suppressor role for its human homologue, Hugl-1. The aims of this study were to characterize Hugl-1 and to determine the clinical significance of Hugl-1 alterations in hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: Sequence alterations of Hugl-1 from 80 HCC specimens and 5 HCC cell lines were characterized by reverse transcription-PCR and sequence analysis. Western blot was used for determining Hugl-1 expression. The biological activities of Hugl-1 and its aberrant variants were examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, wound healing assay, Boyden chamber assay, and tumorigenicity assay. RESULTS: In 32.5% (26 of 80) of the specimens and 20.0% (one of five) of HCC cell lines, 23 unique aberrant Hugl-1 transcripts were identified, most of which resulted from skipping part of and/or entire exon or insertion of intron sequences. The majority of these aberrant Hugl-1 transcripts encoded truncated proteins lacking one or more conserved WD-40 repeat motifs. Two truncated Hugl-1 proteins were found exclusively in HCC tissues. Aberrant Hugl-1 transcripts (78.3%, 20 of 23) had a short "direct repeat" sequence flanking their deleted regions. The abnormal Hugl-1 was significantly correlated with poor differentiation and large tumor size of HCC. Overexpression of two representative HCC-derived aberrant Hugl-1 variants promoted HCC cell migration, invasion, and tumorigenicity in nude mice. CONCLUSIONS: We provide the first evidence that Hugl-1 mRNA is frequently mutated by aberrant splicing exclusively in HCC, which may be involved in HCC progression.
PURPOSE: Lethal giant larvae functions as a cell polarity regulator and a tumor suppressor in Drosophila. Its evolutionary conservation implies a tumor suppressor role for its human homologue, Hugl-1. The aims of this study were to characterize Hugl-1 and to determine the clinical significance of Hugl-1 alterations in hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: Sequence alterations of Hugl-1 from 80 HCC specimens and 5 HCC cell lines were characterized by reverse transcription-PCR and sequence analysis. Western blot was used for determining Hugl-1 expression. The biological activities of Hugl-1 and its aberrant variants were examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, wound healing assay, Boyden chamber assay, and tumorigenicity assay. RESULTS: In 32.5% (26 of 80) of the specimens and 20.0% (one of five) of HCC cell lines, 23 unique aberrant Hugl-1 transcripts were identified, most of which resulted from skipping part of and/or entire exon or insertion of intron sequences. The majority of these aberrant Hugl-1 transcripts encoded truncated proteins lacking one or more conserved WD-40 repeat motifs. Two truncated Hugl-1 proteins were found exclusively in HCC tissues. Aberrant Hugl-1 transcripts (78.3%, 20 of 23) had a short "direct repeat" sequence flanking their deleted regions. The abnormal Hugl-1 was significantly correlated with poor differentiation and large tumor size of HCC. Overexpression of two representative HCC-derived aberrant Hugl-1 variants promoted HCC cell migration, invasion, and tumorigenicity in nude mice. CONCLUSIONS: We provide the first evidence that Hugl-1 mRNA is frequently mutated by aberrant splicing exclusively in HCC, which may be involved in HCC progression.
Authors: Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila Journal: World J Gastroenterol Date: 2010-07-07 Impact factor: 5.742
Authors: Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin Journal: Clin Cancer Res Date: 2013-11-27 Impact factor: 12.531
Authors: Sophia Adamia; Michal Bar-Natan; Benjamin Haibe-Kains; Patrick M Pilarski; Christian Bach; Samuel Pevzner; Teresa Calimeri; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; Ilene Galinsky; Steven Mathews; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Daniel G Tenen; Richard M Stone; James D Griffin Journal: Blood Date: 2014-02-26 Impact factor: 22.113
Authors: Anne E Powell; Chia-Yi Shung; Katherine W Saylor; Karin A Müllendorff; Karin A Müllendorf; Joseph B Weiss; Melissa H Wong Journal: Stem Cell Res Date: 2009-09-25 Impact factor: 2.020